Document Detail


Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.
MedLine Citation:
PMID:  23460379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE: Although febrile neutropenia (FN) is a major source of morbidity and mortality for patients with solid tumors, little is known about the use of guideline-based care.
OBJECTIVES: To examine compliance with guideline-based recommendations for FN treatment, explore the factors that influence adherence to consensus guidelines, and analyze how the use of guideline-based care affects the outcomes.
DESIGN: The Perspective database was used to examine the treatment of cancer patients with FN from January 1, 2000, through March 31, 2010. To capture initial decision making, we examined treatment within 48 hours of hospital admission. We determined use of guideline-based antibiotics and nonguideline-based treatments, vancomycin, and granulocyte colony-stimulating factors (GCSF). Hierarchical models were developed to examine the factors associated with treatment. Patients were stratified into low- and high-risk groups, and the effect of the initial treatment on outcome (nonroutine hospital discharge and death) was examined.
SETTING AND PARTICIPANTS: Twenty-five thousand two hundred thirty-one patients with solid tumors hospitalized for neutropenia.
MAIN OUTCOME MEASURE: Use of guideline-based antibiotics, vancomycin, and GCSF and their affect on outcome.
RESULTS: Among 25 231 patients admitted with FN, guideline-based antibiotics were administered to 79%, vancomycin to 37%, and GCSF to 63%. Patients treated at high FN-volume hospitals (odds ratio [OR], 1.56; 95% CI, 1.34-1.81) by high FN-volume physicians (OR, 1.19; 95% CI, 1.03-1.38) and patients managed by hospitalists (OR, 1.49; 95% CI, 1.18-1.88) were more likely to receive guideline-based antibiotics (P < .05). Vancomycin use increased from 17% in 2000 to 55% in 2010, while GCSF use only decreased from 73% to 55%. Among low-risk patients with FN, prompt initiation of guideline-based antibiotics decreased discharge to a nursing facility (OR, 0.77; 95% CI, 0.65-0.92) and death (OR, 0.63; 95% CI, 0.42-0.95).
CONCLUSIONS AND RELEVANCE: While use of guideline-based antibiotics is high, use of the nonguideline-based treatments, vancomycin, and GCSF is also high. Physician and hospital factors are the strongest predictors of both guideline- and nonguideline-based treatment.
Authors:
Jason D Wright; Alfred I Neugut; Cande V Ananth; Sharyn N Lewin; Elizabeth T Wilde; Yu-Shiang Lu; Thomas J Herzog; Dawn L Hershman
Related Documents :
23354669 - Automatic identification of wet and dry cough in pediatric patients with respiratory di...
23504529 - Indices to assess malocclusions in patients with cleft lip and palate.
11200689 - Essential tremor: an overdiagnosed condition?
24711129 - Increased rates of periprosthetic joint infection in patients with cirrhosis undergoing...
23085729 - Association between oral nutritional supplementation and clinical outcomes among patien...
9294939 - Gradual onset of dysphagia: a study of patients with oculopharyngeal muscular dystrophy.
8701399 - Evaluation of a new rapid quantitative d-dimer assay in patients with clinically suspec...
9835259 - Reproducibility of the adenosine-5'-triphosphate test in vasovagal syndrome.
2719469 - Treatment failure of norfloxacin against campylobacter pylori and chronic gastritis in ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  JAMA internal medicine     Volume:  173     ISSN:  2168-6114     ISO Abbreviation:  JAMA Intern Med     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-09     Completed Date:  2013-06-05     Revised Date:  2013-10-24    
Medline Journal Info:
Nlm Unique ID:  101589534     Medline TA:  JAMA Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  559-68     Citation Subset:  AIM; IM    
Affiliation:
Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. jw2459@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use
Fever / therapy
Guideline Adherence*
Humans
Neoplasms / complications,  drug therapy*
Neutropenia / chemically induced,  therapy*
Practice Guidelines as Topic*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 CA134964/CA/NCI NIH HHS; R01 CA169121/CA/NCI NIH HHS; R01CA134964/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem ...
Next Document:  Controlled synthesis of thorium and uranium oxide nanocrystals.